Detecting disease associated biomarkers by luminescence modulating phages

dc.contributor.authorKulpakko Janne
dc.contributor.authorJuusti Vilhelmiina
dc.contributor.authorRannikko Antti
dc.contributor.authorHänninen Pekka E
dc.contributor.organizationfi=biolääketieteen laitos|en=Institute of Biomedicine|
dc.contributor.organizationfi=lääketieteellinen tiedekunta|en=Faculty of Medicine|
dc.contributor.organization-code1.2.246.10.2458963.20.77952289591
dc.contributor.organization-code2607000
dc.contributor.organization-code2607100
dc.converis.publication-id174961434
dc.converis.urlhttps://research.utu.fi/converis/portal/Publication/174961434
dc.date.accessioned2022-10-28T12:44:28Z
dc.date.available2022-10-28T12:44:28Z
dc.description.abstractAssessment of risk for a given disease and the diagnosis of diseases is often based on assays detecting biomarkers. Antibody-based biomarker-assays for diseases such as prostate cancer are often ambiguous and biomarker proteins are frequently also elevated for reasons that are unspecific. We have opted to use luminescence modulating phages for the analysis of known acute inflammatory response biomarker CRP (C-reactive protein) and biomarkers of prostate cancer in urine samples. Firstly, CRP was used to simulate the detection process in a controlled chemical environment. Secondly, we tried to classify more challenging lethal prostate cancer samples from control samples. Our unique method utilizes a special biopanning process in order to create special phages capable of capturing a dye necessary for detection and potential biomarkers. As the biomarker-molecules interfere with the phages, dye is repelled from the phage network resulting in an altered reporter luminescence. These changes can be observed with an absorbance reader and even with the naked eye. The simple method could present an alternative for screening of disease biomarkers. For prostate cancer urine samples, we achieved a sensitivity of 80% and specificity of 75% to detect Grade Group (GG) 4 and 5 prostate cancer.
dc.identifier.eissn2045-2322
dc.identifier.jour-issn2045-2322
dc.identifier.olddbid178627
dc.identifier.oldhandle10024/161721
dc.identifier.urihttps://www.utupub.fi/handle/11111/36193
dc.identifier.urlhttps://www.nature.com/articles/s41598-022-06433-y
dc.identifier.urnURN:NBN:fi-fe2022081154242
dc.language.isoen
dc.okm.affiliatedauthorKulpakko, Janne
dc.okm.affiliatedauthorHänninen, Pekka
dc.okm.affiliatedauthorJuusti, Vilhelmiina
dc.okm.discipline3111 Biomedicineen_GB
dc.okm.discipline3122 Cancersen_GB
dc.okm.discipline3111 Biolääketieteetfi_FI
dc.okm.discipline3122 Syöpätauditfi_FI
dc.okm.internationalcopublicationnot an international co-publication
dc.okm.internationalityInternational publication
dc.okm.typeA1 ScientificArticle
dc.publisherNATURE PORTFOLIO
dc.publisher.countryUnited Kingdomen_GB
dc.publisher.countryBritanniafi_FI
dc.publisher.country-codeGB
dc.relation.articlenumber2433
dc.relation.doi10.1038/s41598-022-06433-y
dc.relation.ispartofjournalScientific Reports
dc.relation.volume12
dc.source.identifierhttps://www.utupub.fi/handle/10024/161721
dc.titleDetecting disease associated biomarkers by luminescence modulating phages
dc.year.issued2022

Tiedostot

Näytetään 1 - 1 / 1
Ladataan...
Name:
s41598-022-06433-y.pdf
Size:
1.12 MB
Format:
Adobe Portable Document Format